

Q2 FINANCIALS

Q2 Revenue

\$1.7B

+30% from prior-year period

Net Income

\$237M

GAAP diluted earnings per ADS of \$2.05

Gross Margin

90%

from 87% prior year period

COMMERCIAL HIGHLIGHTS



+31%

Sustained global, foundational BTKi leadership



+18%

Japan regulatory approval



U.S. FDA

Accelerated approval

PIPELINE HIGHLIGHTS

- ✦ Positive topline results from the Phase 3 MANGROVE study in treatment-naïve mantle cell lymphoma
- ✦ Five solid tumor programs achieving clinical proof of concept
- ✦ FDA Orphan Drug Designation for our PRMT5 inhibitor in pancreatic ductal adenocarcinoma.

**CANCER
HAS NO BORDERS
NEITHER
DO WE**

*Brand names vary by country.